Diseases Flashcards
What is ACOS?
Asthma / COPD overlap syndrome
Define asthma
A chronic inflammatory disease of both large and small airways. Airway inflammation is the basic underlying process
What is the asthma triad?
- reversible airflow obstruction
- airway inflammation
- airway hyperresponsiveness
What are the hallmarks of remodelling in asthma?
- thickening of the basement membrane
- collagen deposition in the submucosa
- hypertrophy in the smooth muscle
Describe the inflammatory cascade in asthma
- inherited or acquired factors; viral, allergen or chemical
- eosinophilic inflammation
- mediators - TH2 cytokines
- twitch smooth muscle (hyper reactivity)
What would be prescribed for twitchy smooth muscle (hyper reactivity) ? (asthma)
- bronchodilators
- beta 2 agonists
- muscarinic antagonists
What would be prescribed for mediators / TH2 cytokines? (asthma)
- antileukotrienes or antihistamines
- anti IgE
- anti interleukin 5
What would be prescribed for eosinophilic inflammation? (asthma)
- anti-inflammatory medication
- corticosteroids
- cromones
- theophylline
Describe the triggers of asthma
- allergens
- others such as exercise, viral infection, smoke, cold, chemicals, drugs (NSAIDs, beta blockers0
Describe the clinical signs of asthma
- episodic symptoms and signs
- diurinal variability - nocturnal/ early morning
- non productive cough, wheeze
- triggers
- associated atopy, increased IgE (rhinitis, conjunctivitis, eczema)
- blood eosinophilia >4%
- responsive to steroid or beta-agonists
- family history of asthma
- wheezing due to turbulent airflow
Describe the diagnosis of asthma
- history and examination
- diruninal variation of peak flow rate
- reduced forced expiratory ratio (FEV.FVC <75%)
- reversibility to inhaled salbutamol
- provocation testing = bronchospasm
Describe COPD
- a multi-component disease process
- mucociliary dysfunction
- inflammation
- tissue damage
- leads to obstruction of airflow
Describe chronic bronchitis
- chronic neutrophilic inflammation
- mucus hypersecretion
- mucociliary dysfunction
- altered lung microbiome
- smooth muscle spasm hypertrophy
- partially reversible
Describe emphysema
- alveolar destruction
- impaired gas exchange
- loss of bronchial support
- irreversible
Describe the COPD clinical syndrome
- chronic symptoms, not episodic
- smoking
- non atopic
- daily productive cough
- progressive breathlessness
- frequent infective exacerbations
- chronic bronchitis, wheezing
- emphysema, reduced breath sounds
Describe the chronic cascade in COPD
- progressive fixed airflow obstruction
- impaired alveolar gas exchange
- respiratory failure ; decrease PaO2 and increased PaCO2
- pulmonary hypertension
- right ventricular hypertrophy / failure
- death
- stopping smoking arrests further decline in lung volume
Describe ACOS
- COPD with blood eosinophilia >4%
- responds better to ICS with exacerbation reductions
- more reversible to salbutamol
- difficult from asthmatic smokers who have airway remodelling (reduced FVC)
The physiology of hypoventilation leads to what?
Hypoxaemia and then to hypercarbia
What guidelines are used in the treatment of asthma?
Sign guidelines
Describe the challenge test
- use mannitol or histamine
- airways will narrow to a certain extent
Describe the benefit of flu vaccines
- reduce flu rates
- reduce admissions
- reduce severity of flu
- opportunistic vaccination
What are the challenges in primary care of asthma
- non-attendance
- SABA overuse
- who to refer to secondary care
When would you refer for additional investigation and specialist advice for asthma?
- diagnosis unclear
- suspected occupational asthma (symptoms that improve when patient is not at-work, adult onset asthma and workers in high risk occupations)
- poor response to asthma treatment
- severe / life threatening asthma attack
Describe the ‘red flags’ and indicators of other diagnoses in reference to asthma
- prominent systemic features (myalgia, fever, weight loss)
- unexpected clinical findings (eg. crackles, clubbing, cyanosis, cardiac disease, monophonic wheeze or stridor)
- present non-variable breathlessness
- chronic sputum production
- unexplained restrictive spirometry
- chest x-ray shadowing
- marked blood eosinophilia
Name some important mimics of asthma
- COPD
- hypersensitivity pneumonitis
- inducible laryngeal obstruction
- dysfunctional breathing
Describe inducible laryngeal obstruction
- difficulty breathing in rather than out
- feeling of something stuck in the throat
- triggered by exercise, perfume, strong smells, flowers, change in temperature
- not an allergic phenomenon
Describe the effects of smoking
- reduces ciliary beat frequency
- sputum retention
- increased infection
- steroids are much less effective in smokers
- macrolide antibiotics are not effective in smokers
Describe allergic borncho-pulmonary aspergillosis
- an allergic response to aspergillus
- mucus plugging
- proximal bronchiectasis
- total IgE >1000, elevated aspergillus IgE
- treatment = steroids and itraconazole
Describe allergic asthma
- usually childhood onset
- atopic triad; asthma, eczema, rhinitis
- typically allergic to; HDM, grass, cats and dogs
- dermatographism
- treatment options; Montelukast, antihistamines, allergen avoidance, omalizumab (monoclonal antibody to IgE
Describe eosinophilic asthma
- usually adult onset
- female preponderance
- usually more steroid resistant
- often stuck on prednisolone
- anti-allergen therapy not effective
- anti IL5 therapy; mepolizumab, benralizumab
A combination of severe asthma is recognised by what criteria?
- previous near fatal asthma eg. previous ventilation or respiratory acidosis
- previous admission for asthma, especially in the last year
- requiring three or more classes of asthma medication
- heavy use of a beta 2 agonist
- repeated attendances at ED for asthma care, especially in the last year
AND adverse behavioural or physiological features
Name the clinical signs of life-threatening asthma
- altered conscious level
- exhaustion
- arrhythmia
- hypotension
- cyanosis
- silent chest
- poor respiratory effort
- PEF <33% best or predicted
- SpO2 <92%
- PaO2 <8 kPa
- normal PaCO2
What are the co-morbidities associated with COPD?
- heart failure
- ischaemic heart disease
- obesity
- interstitial lung disease
- bronchiectasis
Describe the pharmacological management of COPD
- bronchodilators
- inhaled corticosteroids
- combination therapies
- oral therapies
Describe the use of bronchodilators in stable COPD
- LABA and LAMA significantly improve lung function, dyspnoea, health status and reduce exacerbation rates
- LAMA have a greater effect on exacerbation and decrease hospitalisations
- LABA/LAMA combination increases FEV1 and reduces symptoms compared with monotherapy
- theophylline exerts a small bronchodilator effect in COPD
Describe inhaled corticosteroids in COPD
- an ICS combined with LABA is more effective than the individual components in improving lung function and health status
- regular treatment with ICDS increases the risk of pneumonia, especially in those with severe disease
- triple inhaled therapy improves lung function, symptoms and health status
When would you consider use of ICS treatment in COPD?
- one moderate exacerbation of COPD per year
- blood eosinophils 100-300 cells / ul
What factors go against use of ICS in COPD
- repeated pneumonia events
- blood eosinophils <100 cells/ ul
- history of mycobacterial infection
What are the key principles in treating COPD?
- accurate diagnosis
- treat co-morbidities
- smoking cessation
- vaccinations
- pulmonary rehab
- LABA/LAMA
- trial of triple if high eos or frequent exacerbator
Who do you refer to secondary care in terms of COPD?
- diagnosis uncertain
- rapidly declining FEV1
- for consideration of; LVRS, bronchoscopic values, lung transplant
Describe exacerbations in COPD
- an exacerbation of COPD is defined as an acute worsening of respiratory symptoms that results in additional therapy
- the symptoms are not specific to COPD - relevant differential diagnoses should be considered
- exacerbation of COPD can be precipitated by several factors
- the goal of treatment is to minimise the negative impact of the current exacerbation
Name the differential diagnoses of COPD exacerbation
- pneumonia
- pneumothorax
- pleural effusion
- pulmonary embolism
- pulmonary oedema
- cardiac arrhythmias
Describe exacerbation in COPD
- increased short acting bronchodilators are recommended as initial management
- systemic steroids can improve lung function, oxygenation and shorten recovery time. Duration of therapy should not be more than 5-7 days
- antibiotics, when indicated, can shorten recovery time, reduce the risk of early relapse, treatment failure. Duration of therapy should be 5-7 days
Describe the approach in clinic in COPD
- confirm the diagnosis of COPD
- determine if there are additional diagnoses or exacerbating factors, particularly compliance
- optimise therapy
- consider surgical options
- discuss anticipatory care and end of life management
Name the surgical options for COPD
- bullectomy
- lung volume reduction surgery
- endobronchial valves and coils
- lung transplant
Describe bullectomy
- for bullae that occupy more than 50% of the thoracic cavity
- not without challenge
- need some other lung expand to take its place
- giant bullae are often associated with cannabis use
Describe volume reduction surgery
- effective for more heterogenous bullous emphysema
- surgical removal of the upper lobe(s)
- rarely done these days
- must have been through PR
Describe endobronchial valves/coils
- new technology
- one way valves of self collapsing coils inserted via a bronchoscope
- block ventilation to bullae, and areas of poor V/Q matching
Describe non-invasive ventilation
- two levels of pressure
- expiratory positive
- expiratory positive airway pressure; lowers the work of breathing, overcomes intrinsic PEEP, reduces pCO2
- inspiratory positive airways pressure; increases tidal volume and minute volume, reduces pCO2
What are the important considerations of non-invasive ventilation
- will the patient tolerate the mask
- does the patient have an ACP to avoid NIC
- what will we do if NIV fails
Describe the clinical presentation of pulmonary neoplasia
- local effects; obstruction of the airway, invasion of chest wall, ulceration
- metastases; nodes, bones, liver, brain
- systemic effects; weight loss, ectopic hormone production
Describe small cell cancer
- rapidly progressive disease
- early metastases
- rarely suitable for surgery, most of the time at first presentation, it has spread beyond the primary site
- good initial response to chemotherapy
- the rapid growth of the tumour makes it more susceptible to cytotoxic chemotherapy, often backed up with radiotherapy
Describe non-small cell cancer
- includes squamous and adenocarcinomas
- curative options are surgery or radical radiotherapy
- palliative chemotherapy and new targeted treatment
- account for the majority of lung cancers
Describe cytotoxic chemotherapy
- rarely curative but longer survival
- better response in small cell cancer
- major side effects
- intravenous infusions every 3-4weeks
- outpatient visits
- more detailed imaging
- whole body treatment
- targets rapidly dividing cells
- blood brain barrier; prophylactic cranial irradiation
Name some chemotherapy side effects
- nausea and vomiting
- tiredness
- bone marrow suppression
- opportunistic infection
- anaemia
- hair loss
- pulmonary fibrosis
Describe radiotherapy
- ionising radiation
- usually xrays
- external beam
- radical; curative treatment
- palliative; delaying tactic, useful for metastases
- well tolerated
Name some cons of radiotherapy
- maximum cumulative dose
- collateral damage- spinal cord, oesophagus, adjacent lung tissue
- only goes where you point the beam
- not suitable for subclinical metastases
Describe stereotatic ablative radiotherapy (SABR)
- many more beams
- each beam is less powerful;
- less collateral damage
- total dose delivered to tumour is higher and more effective
- 4D scanning required
Describe endobronchial therapy
- stent insertion for stridor
- photodynamic therapy
- other laser therapy
Describe histological diagnosis of pulmonary neoplasia
- bronchoscopy and biopsy of the tumour if seen
- biopsy or needle aspiration metastases (especially mediastinal or supraclavicular lymph nodes)
- endobronchial ultrasound guided specimens
- we need a microscope diagnosis and also sufficient tissue for identification of molecular predictor or response to treatment
What is pleural effusion?
- abnormal collection of fluid
- common presentation of numerous diseases
- does not always require drainage or sampling
- large unilateral effusions should raise concern
Describe the workup for pleural effusion
- history and examination
- PA CXR
- pleural aspirate
- biochemistry (transudate or exudate)
- cytology
- culture
- other tests; contrasted enhanced CT chest, repeat pleural tap, pleural biopsy (blind or thorascopy)
Describe the different appearances of pleural effusion and what they suggest
- straw coloured = cardiac failure, hypalbuminaemia
- bloody = trauma, malignancy, infection, infarction
- turbid / milky = empyema, chylothorax, smells
- foul smelling = anaerobic empyema
- food particles = oesophageal rupture
- bilateral = LVF (heart failure), PTE, drugs, systemic path